Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | hypothetical protein | 0.074 | 0.2852 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.074 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1254 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1233 | 0.9706 | 0.9706 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.1254 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1233 | 0.9706 | 0.9604 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1254 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1254 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1233 | 0.9706 | 0.9706 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.1233 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1254 | 1 | 1 |
Onchocerca volvulus | 0.1254 | 1 | 0.5 | |
Giardia lamblia | Hypothetical protein | 0.074 | 0.2852 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.1254 | 1 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.074 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1254 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.074 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1233 | 0.9706 | 0.9706 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 18 % | Cytotoxicity against human KB cells assessed as growth inhibition at 10 '-6 M after 72 hrs by MTS assay | ChEMBL. | 22257529 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.